Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
- Abstract
- Background: ATTRACTION-2 demonstrated that nivolumab improved overall survival (OS) vs placebo in patients with advanced gastric cancer treated with ≥ 2 chemotherapy regimens. However, its long-term efficacy and outcome of treatment beyond progression (TBP) with nivolumab have not been clarified.
Methods: The 3-year follow-up data were collected. A subset analysis was performed to explore the efficacy of TBP by assessing postprogression survival (PPS) after the first event of disease progression.
Results: Overall, 493 patients were randomized (2:1) to receive nivolumab (n = 330) or placebo (n = 163). With a median follow-up of 38.5 (range 36.1-47.5) months, OS of the nivolumab group was significantly longer compared to the placebo group (median 5.3 vs 4.1 months; 3-year survival rate, 5.6% vs 1.9%; hazard ratio [HR], 0.62 [95% confidence interval (CI) 0.50-0.75], P < 0.0001). The median OS of responders (n = 32) who achieved complete response or partial response was 26.7 months and the 3-year survival rate was 35.5% in the nivolumab group. Overall, 109 patients in the nivolumab group and 37 patients in the placebo group received TBP. PPS tended to be longer in the nivolumab group vs placebo group (median 5.8 vs 4.5 months; HR [95% CI], 0.69 [0.47-1.01], P = 0.057). In contrast, PPS was similar between both treatment groups in non-TBP patients (median 2.3 vs 2.2 months; HR 0.90, P = 0.42).
Conclusions: Long-term efficacy of nivolumab was confirmed at the 3-year follow-up, and a survival benefit of TBP with nivolumab was suggested. Biomarkers for selecting patients suitable for TBP with nivolumab should be identified in the future.
- Author(s)
- · Li?Tzong Chen; · Li?Yuan Bai1; · Taihei Nishiyama; 강윤구; 유민희; Do?Youn Oh; Hyun Cheol Chung; Jae Yong Cho; Jen?Shi Chen; Jong Gwang Kim; Kei Muro; Keiko Minashi; Keisho Chin; Ken Kato; Keun?Wook Lee; Kun?Huei Yeh; Masahiro Tsuda; Narikazu Boku; Sang Cheul Oh; Takaki Yoshikawa; Takao Tamura; Taroh Satoh; Won Ki K
- Issued Date
- 2021
- Type
- Article
- Keyword
- ATTRACTION-2; Gastric or gastroesophageal junction cancer; Long-term efficacy; Nivolumab; Treatment beyond progression
- DOI
- 10.1007/s10120-021-01173-w
- URI
- https://oak.ulsan.ac.kr/handle/2021.oak/8404
https://ulsan-primo.hosted.exlibrisgroup.com/primo-explore/fulldisplay?docid=TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8205916&context=PC&vid=ULSAN&lang=ko_KR&search_scope=default_scope&adaptor=primo_central_multiple_fe&tab=default_tab&query=any,contains,Nivolumab%20in%20previously%20treated%20advanced%20gastric%20cancer%20(ATTRACTION-2):%203-year%20update%20and%20outcome%20of%20treatment%20beyond%20progression%20with%20nivolumab&offset=0&pcAvailability=true
- Publisher
- GASTRIC CANCER
- Location
- 일본
- Language
- 영어
- ISSN
- 1436-3291
- Citation Volume
- 24
- Citation Number
- 4
- Citation Start Page
- 946
- Citation End Page
- 958
-
Appears in Collections:
- Medicine > Medicine
- Authorize & License
-
- Files in This Item:
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.